Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Phytotherapy for benign prostatic hyperplasia

Bibliographic Data

ID15097638
AuthorsTimothy J Wilt (0000-0002-6019-7779, Minneapolis VA Health Care System, corresponding author), Areef Ishani (0000-0002-1542-2076, Minneapolis VA Health Care System), Indulis Rutks (Minneapolis VA Health Care System), Roderick Macdonald (0000-0002-0276-6558, Minneapolis VA Health Care System)
Year2000
Volume3
Issue4a
Pages459-472
Publication date2000-12-01
Open AccessYes
TypeARTICLE
VenuePublic Health Nutrition (JOURNAL)
Journal identifiersISSN: 1368-9800 • E-ISSN: 1475-2727
PublisherCambridge University Press (CUP) (PUBLISHER)
DOI10.1017/s1368980000000549
PMID11276294
OpenAlexW2100970112
LanguageEN
Citations received2
References cited36

Objective To systematically review the existing evidence regarding the efficacy and safety of phytotherapeutic compounds used to treat men with symptomatic benign prostatic hyperplasia (BPH). Design Randomized trials were identified searching MEDLINE (1966–1997), EMBASE, Phytodok, the Cochrane Library, bibliographies of identified trials and review articles, and contact with relevant authors and drug companies. The studies were included if men had symptomatic benign prostatic hyperplasia, the intervention was a phytotherapeutic preparation alone or combined, a control group received placebo or other pharmacologic therapies for BPH, and the treatment duration was at least 30 days. Key data were extracted independently by two investigators. Results A total of 44 studies of six phytotherapeutic agents ( Serenoa repens , Hypoxis rooperi , Secale cereale , Pygeum africanum , Urtica dioica , Curcubita pepo ) met inclusion criteria and were reviewed. Many studies did not report results in a method allowing meta-analysis. Serenoa repens , extracted from the saw palmetto, is the most widely used phytotherapeutic agent for BPH. A total of 18 trials involving 2939 men were reviewed. Compared with men receiving placebo, men taking Serenoa repens reported greater improvement of urinary tract symptoms and flow measures. Serenoa repens decreased nocturia (weighted mean difference (WMD)=−0.76 times per evening; 95% CI=−1.22 to −0.32; n=10 studies) and improved peak urine flow (WMD=1.93 ml s −1 ; 95% CI=0.72 to 3.14, n=8 studies). Men treated with Serenoa repens rated greater improvement of their urinary tract symptoms versus men taking placebo (risk ratio of improvement=1.72; 95% CI=1.21 to 2.44, n=8 studies). Improvement in symptoms of BPH was comparable to men receiving the finasteride. Hypoxis rooperi (n=4 studies, 519 men) was also demonstrated to be effective in improving symptom scores and flow measures compared with placebo. For the two studies reporting the International Prostate Symptom Score, the WMD was −4.9 IPSS points (95% CI=−6.3 to −3.5, n=2 studies) and the WMD for peak urine flow was 3.91 ml s −1 (95% CI=0.91 to 6.90, n=4 studies). Secale cereale (n=4 studies, 444 men) was found to modestly improve overall urological symptoms. Pygeum africanum (n=17 studies, 900 men) may be a useful treatment option for BPH. However, review of the literature has found inadequate reporting of outcomes which currently limit the ability to estimate its safety and efficacy. The studies involving Urtica dioica and Curcubita pepo are limited although these agents may be effective combined with other plant extracts such as Serenoa and Pygeum . Adverse events due to phytotherapies were reported to be generally mild and infrequent. Conclusions Randomized studies of Serenoa repens , alone or in combination with other plant extracts, have provided the strongest evidence for efficacy and tolerability in treatment of BPH in comparison with other phytotherapies. Serenoa repens appears to be a useful option for improving lower urinary tract symptoms and flow measures. Hypoxis rooperi and Secale cereale also appear to improve BPH symptoms although the evidence is less strong for these products. Pygeum africanum has been studied extensively but inadequate reporting of outcomes limits the ability to conclusively recommend it. There is no convincing evidence supporting the use of Urtica dioica or Curcubita pepo alone for treatment of BPH. Overall, phytotherapies are less costly, well tolerated and adverse events are generally mild and infrequent. Future randomized controlled trials using standardized preparations of phytotherapeutic agents with longer study durations are needed to determine their long-term effectiveness in the treatment of BPH

Alternative medicine · Cochrane Library · Gynecology · Lower urinary tract symptoms · Nocturia · Pathology · Phytotherapy · Placebo · Prostate · Randomized controlled trial · Traditional medicine · Urinary system · Medicinal plant effects and applications · Medicine · Sexual function and dysfunction studies · Urinary Bladder and Prostate Research · Internal Medicine · Urology

  • Post-marketing safety profile and potential aspirin interaction of Serenoa repens extract

    Open Access•Bingjian Guo, Ziwei Zou et al.•Journal of Ethnopharmacology•2027

  • Pharmacological characterization and chemical fractionation of a liposterolic extract of saw palmetto (Serenoa repens)

    Open Access•Thiam Chua, Nicole T Eise et al.•Journal of Ethnopharmacology•2014

  • Systematic Reviews

    Open Access•C D Mulrow•BMJ•1994

Citations per year0.17
Citation span2014 - 2027 (14)
Highly citedNo

Tools

Open DOISci-HubOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae